Feyza Altunbaş Yalabık

Feyza Altunbaş Yalabık

Auto-generated profile, based on publicly available information

Feyza Altunbaş Yalabık

Genetic Disease Diagnosis and Evaluation Center, İzmir City Hospital, İzmir, Turkey

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

13 November 2026 in Journal of Current Hematology & Oncology Research
Verified
Journal Article
Closed access
MYMustafa Kemal Yeniay
Mustafa Kemal Yeniay
OBOzlem Boz
Ozlem Boz
FYFeyza Altunbaş Yalabık
Feyza Altunbaş Yalabık
ZÖZehra Narlı Özdemir
Zehra Narlı Özdemir
OBOktay Bilgir
Oktay Bilgir
Aims: To evaluate the association of fluorescence in situ hybridization (FISH)-defined cytogenetic risk and baseline positron emission tomography/computed tomography (PET/CT) findings with early treatment response and early disease progression in patients with newly diagnosed multiple myeloma (MM). Methods: Seventy patients with newly diagnosed MM were included in this retrospective study. Clinical characteristics, International Staging System (ISS) and Revised ISS (R-ISS) stage, lactate dehydrogenase (LDH) level, FISH-defined cytogenetic risk, and baseline PET/CT parameters, including the number of focal lesions, maximum standardized uptake value (SUV max), extramedullary disease, bone marrow involvement, and metabolic risk group, were recorded. Treatment responses after the second and fourth cycles were evaluated. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method, and exploratory associations with PFS were assessed using Cox proportional hazards regression. Results: According to baseline PET/CT, 81.4% of patients were classified as having a metabolically high-risk disease. Compared with the metabolically low-risk group, patients in the metabolically high-risk group achieved significantly higher rates of very good partial response (VGPR) after the second cycle (49.1% vs. 15.4%, p=0.032) and ≥VGPR after the fourth cycle (64.9% vs. 23.1%, p=0.011). However, progression rates did not differ significantly between the two groups (p=0.675). Although response rates and progression frequency were numerically higher in the FISH high-risk group, these differences did not reach statistical significance. Kaplan–Meier analysis demonstrated longer PFS in female patients (p=0.001); ≥VGPR after the fourth cycle was not significantly associated with PFS (p=0.116). In the multivariable Cox model (13 PFS events), female sex remained significantly associated with PFS (HR=0.067, 95% CI 0.008–0.569, p=0.013), although the estimate was unstable because of the very limited number of events. The 1-year PFS and OS rates were 86% and 92%, respectively. Conclusion: In this exploratory cohort, the study-specific PET/CT metabolic risk classification was associated with deeper early treatment responses but not with short-term disease progression. FISH-defined cytogenetic risk was not significantly associated with early response or progression. Given the short follow-up duration, limited number of events, and lack of external validation of the metabolic risk classification, these findings should be considered preliminary and do not establish the independent prognostic value of PET/CT or FISH-defined risk.

8 March 2025 in Egyptian Journal of Medical Human Genetics
Verified
Journal Article
Open access
PDF file
APAlp Peker
Alp Peker
ÖCÖzden Altıok Clark
Özden Altıok Clark
MCMert Coşkun
Mert Coşkun
ADAli Duru
Ali Duru
FYFeyza Altunbaş Yalabık
Feyza Altunbaş Yalabık
EMErcan Mıhçı
Ercan Mıhçı
Background: This study presents an adult 7p21 deletion patient, including a literature review specific to 7p21 deletion, and concludes recommendations toward such patients. A 47-year-old male with moderate-to-severe learning disability and significant dysmorphic features was seen in our Medical Genetics clinic. Initially, a chromosome analysis was requested considering a pre-diagnosis of Down syndrome with adult age, and other chromosomal abnormalities. Results: In karyotype analysis, one chromosome 7 was observed to have a deletion on its short arm. Subsequently, single nucleotide polymorphism array (SNP Array) analysis was pursued to confirm the abnormality seen in the chromosome analysis and to elucidate its details. The results indicated a 16-megabase loss in the 7p21.3-p15.3 regions. Conclusions: Patients with deletions of the short arm of chromosome 7 may exhibit various phenotypic features, including case-specific anomalies. Common abnormalities often linked to the heterozygous loss of 7p21 include a wide nasal bridge and ear shape abnormalities. Our 47-year-old patient presented with macroglossia and dysmorphic traits, suggesting macroglossia as a potential clinical finding for follow-up in adults. Further research is needed to confirm if all such specific anomalies are due to 7p genetic material loss.

5 November 2026 in Journal of Pediatric and Adolescent Gynecology
Verified
Journal Article
Closed access
MKMURAT ÇAĞLAR KARATAŞ
MURAT ÇAĞLAR KARATAŞ
OKOzge Koprulu
Ozge Koprulu
TCTayfun Cinleti
Tayfun Cinleti
ÖKÖzge Özer Kaya
Özge Özer Kaya
SASezer Acar
Sezer Acar
BÖBehzat Özkan
Behzat Özkan